Technology for Fighting Heart Disease

by | Jul 28, 2021 | Healthcare, Human Factors, QMS, Treatment

Coronary heart disease (CHD), or coronary artery disease (CAD), is the leading cause of death globally. In the United States, CHD is the leading cause of death in adults, accounting for nearly one-third of the total deaths in individuals over the age of 35 years old. Modern advancements in CHD treatment have shown improvement in these concerning statistics, which is most noticeable during the decade of 2003 to 2013 when the annual death rate declined 38.0%1.  

Atherosclerosis is the reason for clogging of the coronary artery, defined as the buildup of cholesterol and fatty deposits (plaque) within the lumen of the artery, thereby restricting blood flow. A commonly used interventional procedure for CHD is generally called an angioplasty, more specifically a percutaneous coronary intervention. At a very basic level, a stent is guided through an inserted catheter running through an artery of the groin to the target vessel occlusion site. Once in the proper location where the plaque buildup is located, the stent is implanted via expansion and the catheter is removed2. Modern stents are coated with a drug that reduces pathological and vascular remodeling that thickens the vascular wall from eliciting the body’s immune response. Stents used in today’s operation are highly engineered medical implants with decades of work fine-tuning the optimal geometrical shape, effective drug coating, sterilization techniques, implantation procedure, among other components3.  

A recent innovation has initiated investigative approaches into degradable polymers because they are metabolized by the immune response at an expected rate via material engineering. These degradable polymers can be loaded with the desired drug so the dosage profile overtime may be manipulated. Furthermore, new coating techniques allow for the drug to specifically target the contacted blood vessel endothelial cells3

Class III devices such as cardiovascular stents are needed for treating serious threats to public health. Changes are inevitable as technology advances and knowledge of the factors associated with these devices become understood. However, the quality and regulatory standards for manufacturing such high-risk devices shall always have the highest importance and attention. A robust, well-developed foundational Quality Management System (QMS) shall easily incorporate the compliance needs of all QA/RA enforcing bodies. The experts at EMMA International have a plethora of knowledge across multiple sectors of MedTech that consistently proves to be useful in grasping fundamental operations, procedures, and documentation required for maintaining an effective and adaptable QMS. Give us a call at 248-987-4497 or email us at info@emmainternational.com to learn more about how EMMA International can help will all things quality and regulatory. 

[1] Sanchis-Gomar, F., Perez-Quilis, C., Leischik, R., & Lucia, A. (2016). Epidemiology of coronary heart disease and acute coronary syndrome. Annals of Translational Medicine, 4(13), 256–256. Retrieved on 27 July 2021 from: https://doi.org/10.21037/atm.2016.06.33 

[2] Cleveland Clinic (2019) Cardiac Catheterization & Coronary Angioplasty and Stent (Interventional Procedures).Retrieved on 27 July 2021 from: https://my.clevelandclinic.org/health/treatments/16833-cardiac-catheterization–coronary-angioplasty-and-stent-interventional-procedures 

[3] Elsevier Science & Technology, edited by Gerald Wall, et al. (2017) Functionalized Cardiovascular Stents. Retrieved on 27 July 2021 from: https://ebookcentral.proquest.com/lib/wayne/detail.action?docID=5051423

‌ 

Zach Nies

Zach Nies

Quality Engineer (Co-Op) - Mr. Nies has experience in combination products, pharmaceuticals, and FDA compliance for many life science industries. He has experience with many different elements of quality and regulatory compliance. Mr. Nies is completing a Bachelor of Engineer degree in Biomedical Engineering from Wayne State University.

More Resources

The End of the COVID-19 Public Health Emergency

The End of the COVID-19 Public Health Emergency

After over 3 years, the COVID-19 Public Health Emergency (PHE) will end on May 11, 2023, the Biden Administration announced last week.1After 3.5 years of the modified policy to allow for amore efficient path for COVID-19-related medical products to get to market, this begs the question of how it will impact the MedTech world.
Process Validation

Process Validation

All right, you have just gotten all of your paperwork together, submitted the right forms to the right people, set up your factory, hired and trained your staff; now it’s time to make the medical devices. The regulatory nonsense is over and done, right?
The Role of Management in Product Quality

The Role of Management in Product Quality

Depending on the factory, some production employees may find it surprising that management has an important role to play in a quality system.  21 CFR 820.20 mandates that “Management with executive responsibility shall establish objectives for, and commitment to, quality”.[1]  The Federal Government expects that management takes an active interest in improving the output of their company, at least in the case of medical device manufacturers.

Ready to learn more about working with us?

Pin It on Pinterest

Share This